Dr. Rini Explains the Axitinib Integration Process
Lead investigator Brian I.
Dr. Rini Describes Axitinib's and Sorafenib's Side Effects
Lead investigator Brian I.
Dr. Rini on Axitinib for Treatment of Metastatic Renal Cell Carcinoma
Brian
Dr. Rini Discusses the VEGF Targeted Agent Axitinib
Brian
Dr. Rini on the Efficacy of Axitinib and Pembrolizumab in RCC
Brian I.
Dr. Rini on the Axitinib and Sorafenib Trial VEGF Focus
Lead investigator Brian I.
Dr. Rini Describes Hypertension as a Biomarker in RCC
Lead investigator Brian I.
Dr. Rini on Managing the Toxicity of Pembrolizumab Plus Axitinib in mRCC
Brian I.
Dr. Rini on the Results From His Axitinib and Sorafenib Trial
Brian
Dr. Rini on Pembrolizumab Plus Axitinib in RCC
Brian I.
Axitinib IS the New Standard of Care in 2nd-line: PRO Brian I. Rini, M.D.
Axitinib
Dr. Rini on the Axitinib and Sorafenib Trial Hazard Ratio
Brian
Dr. Rini Discusses Pembrolizumab Plus Axitinib in mRCC
Brian I.